Quarterly Results Review & Outlook: Complementary Reports on Costco, Chevron, ImmunoGen, MasterCard, and Intercept

NEW YORK, February 2, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Costco (NASDAQ: COST), Chevron (NYSE: CVX), ImmunoGen (NASDAQ: IMGN), MasterCard (NYSE: MA), and Intercept (NASDAQ: ICPT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

COST Research Report: ( http://get.analystsreview.com/pdf/?c=Costco&d=2-Feb-2015&s=COST ),

CVX Research Report: ( http://get.analystsreview.com/pdf/?c=Chevron&d=2-Feb-2015&s=CVX ),

IMGN Research Report: ( http://get.analystsreview.com/pdf/?c=ImmunoGen&d=2-Feb-2015&s=IMGN ),

MA Research Report: ( http://get.analystsreview.com/pdf/?c=MasterCard&d=2-Feb-2015&s=MA ),

ICPT Research Report: ( http://get.analystsreview.com/pdf/?c=Intercept&d=2-Feb-2015&s=ICPT ).

============

--

Analyst Update: Business Outlook, FDA Approvals, Dividend Declarations, and Financial Results

Reviewed by: Rohit Tuli, CFA®  

The U.S. stocks ended lower on Friday, sending the S&P 500 index to its biggest monthly decline in a year, as an unexpected deceleration in the U.S. fourth quarter GDP growth raised concerns over the health of world's biggest economy, curbing appeal of the risky assets. A Commerce Department data on Friday showed that the U.S. economy grew at a slower-than-expected 2.6% annualized rate in the fourth quarter versus a 5% growth in the third quarter as businesses curbed spending while trade deficit widened. The Dow Jones Industrial Average declined 1.45% to close at 17,164.95, the S&P 500 fell 1.30% to close at 1,994.99, and the Nasdaq Composite slipped 1.03% to end at 4,635.24. European equities also ended lower on Friday as data showed that consumer prices in the euro area fell more than the forecasts in January, highlighting the challenges that European Central Bank faces in its battle with deflation. Meanwhile, Asian stocks edged up on Friday, taking cues from the Wall Street where stocks rose on back of strong earnings.

Costco Wholesale Corporation (Costco) declared a special cash dividend of $5 per share; stock was up 1.67% in trade. The dividend which is payable on February 27, 2015, to shareholders of record as of the close of business on February 9, 2015, is in addition to the Company's regular quarterly cash dividend of $0.355 per share that was declared on January 29, 2015.

Chevron Corporation (Chevron) surpassed Q4 2014 earnings expectations and announced a $35.0 billion capital and exploratory investment program, down 13% from prior year figure, as the Company "tests its short-cycle investments, at current prices and are selecting only the most attractive opportunities to move forward."

Shares of ImmunoGen, Inc. (ImmunoGen) in skyrocketed as the Company reported better-than-expected Q2 FY 2015 financial results. For FY 2015 ImmunoGen reiterated its earlier guidance range of $100 million to $105 million in revenues and net loss between $60 million and $65 million.

Shares of MasterCard Inc. (MasterCard) eke out gain after the Company reported stronger Q4 2014 results. Worldwide purchase volume during the reporting quarter was up 12% YoY on a local currency basis, to $858 billion.

Shares of Intercept Pharmaceuticals Inc (Intercept) rallied almost 18% after the Company announced that its investigational product obeticholic acid has received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED